Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JMM who wrote (5139)	8/13/1998 3:50:00 PM
From: Joe E.	Read Replies (2) \| Respond to of 6136

JMM: <<No where in the overseas mkt can they afford the cost associated with the treatment. >> Actually they can afford it in Europe. And Japan. Australia, possibly New Zealand. And in a few parts of the Middle East. And a small proportion of people in other places too. I normally figure that the market potential for the "rest of the world" is roughly equal to the market potential in the US.

To: JMM who wrote (5139)	8/13/1998 4:03:00 PM
From: Zirdu	Respond to of 6136

<<It's ironic that its a disease that people want to control and have less of... but some companies have it as a growth vehicle for profits.>> Huh?? I don't see the irony here. Don't people "want to control and have less of " ALL diseases? And doesn't EVERY drug company that makes a drug that targets any disease, see that drug "as a growth vehicle" for their company? I'd say this system (i.e. companies with a profit motive developing drugs to combat diseases) has worked well at developing many amazing new drugs we wouldn't otherwise have. And in the long run, all you have to do is wait a few years and all these drugs will be "off patent", so any company can manufacture and sell them without royalties.

To: JMM who wrote (5139)	8/13/1998 4:37:00 PM
From: sam	Respond to of 6136

OTOTOTOT <<It's ironic that its a disease that people want to control and have less of... but some companies have it as a growth vehicle for profits.>> Yea -- shame on Merck and AGPH for wanting to give AIDs patients some quality of life. And shame on me for being an AGPH profiteer. What I find potentially "ironic" is that there are people shorting the heck out of companies doing cancer research. And, by shorting those companies, those "investors" actually make it harder for the companies to do research (i.e. leveraging their stock for purposes of...say...enticing researchers or keeping them inhouse with options packages). The "irony," of course, would be if any of those "investors" actually get cancer themselves. BTW, what disease do people want MORE of?